(856) 485-9814

Heroin & Opioid Addiction Treatment · Integrated With Residential Care

Heroin & Opioid Addiction Treatment in South Jersey & Greater Philadelphia

Residential Recovery for Heroin, Fentanyl & Prescription Opioid Use Disorder in Merchantville, NJ

For patients and families in South Jersey, Cherry Hill, Camden County, or Greater Philadelphia searching for heroin addiction treatment, residential opioid rehab near Philadelphia, or fentanyl-aware care that continues MAT — Maplewood Treatment Solutions delivers evidence-based residential treatment for opioid use disorder. We continue Suboxone, Vivitrol, and other MAT prescriptions. We treat the trauma, anxiety, depression, and PTSD that often drive opioid use. Patients are treated with dignity, respect, and individualized clinical care — including no forced taper of MAT as a condition of admission.

Joint Commission Accredited  |  LegitScript Certified  |  NJ Licensed Treatment Center

✓ Medically reviewed byEdward Pearson, MD · Medical Director·Last reviewed: May 13, 2026

Accreditations & Certifications

Accredited/Certified by Joint Commission Chamber of Commerce of Southern New Jersey Member Verify LegitScript Approval

The Short Version

What Heroin & Opioid Treatment Means at Maplewood — In Plain English

Heroin and opioid addiction treatment at Maplewood is residential clinical care designed for the specific clinical realities of opioid use disorder — high relapse risk in early recovery, post-acute withdrawal symptoms that can persist for weeks, the real possibility of fentanyl contamination in today’s drug supply, and co-occurring mental health conditions in roughly half of patients. Our program continues Suboxone, Vivitrol, and other MAT prescriptions, integrates trauma-informed care and dual diagnosis treatment, and connects you to outpatient MAT continuity before you leave residential.

A Chronic Medical Condition, Not a Moral Failure

What Heroin and Opioid Addiction Actually Is in Clinical Terms

Opioid use disorder is a clinically defined condition recognized by the American Psychiatric Association in the DSM-5 and treated as a chronic medical disease by the National Institute on Drug Abuse. It includes patterns of opioid use that meet diagnostic criteria for tolerance, withdrawal, loss of control, and continued use despite negative consequences.

In practice, opioid use disorder presents in many forms. For some patients, the path began with prescription painkillers — oxycodone, hydrocodone, Percocet, OxyContin — that originally treated legitimate pain. For others, the entry point was heroin. Increasingly, patients arrive having used substances they believed were one thing *(heroin, counterfeit pills)* that were contaminated with fentanyl — a synthetic opioid 50 to 100 times more potent than morphine.

The clinical reality of opioid addiction in 2026 is shaped by three factors that did not exist a decade ago at the current scale: widespread fentanyl contamination, broad evidence-based acceptance of Medication-Assisted Treatment, and recognition that opioid use disorder is rarely a standalone clinical issue — it commonly co-occurs with depression, anxiety, PTSD, and chronic pain. Effective residential treatment has to address all of it.

Medication-Assisted Treatment → Co-Occurring Disorders Program →

Specialized Care Across Opioid Use Disorder Presentations

Who We Treat for Opioid Use Disorder at Maplewood

Opioid use disorder does not look the same in every patient. Treatment plans are individualized based on substance, history, co-occurring conditions, and life circumstances. Maplewood treats patients across the following presentations:

Prescription Opioid Addiction
Patients whose opioid use began with prescribed Percocet, Oxycontin, Vicodin, Tramadol, or post-surgical pain management and progressed to dependence or use disorder.
Heroin Addiction
Patients with active or recent heroin use — including those who transitioned from prescription opioids to heroin, and those navigating today’s fentanyl-contaminated supply.
Fentanyl Addiction
Patients with known fentanyl use, suspected fentanyl exposure through counterfeit pills, or repeated overdose history reflecting fentanyl-era risk patterns.
Young Adults
Adults in their late teens through twenties facing opioid use disorder — often with overlapping anxiety, depression, ADHD, or trauma histories that complicate recovery.
Working Professionals
Patients balancing career, family, and licensure considerations — including healthcare workers, executives, and others who require discreet, confidential clinical care.
Chronic Pain Patients
Patients with co-existing chronic pain and opioid use disorder, where coordinated psychiatric, medical, and pain-management strategies are part of the treatment plan.
Co-Occurring Mental Health
Patients with opioid use disorder alongside depression, anxiety, PTSD, bipolar disorder, or ADHD — treated through our integrated dual diagnosis program.
Patients Returning to Treatment
Patients with prior treatment, relapse, or detox history. Returning to treatment is a clinical reality of opioid use disorder — not a failure. Our team works with what has and has not worked before.

The Numbers Behind the Crisis

The Scale of Opioid Addiction in the U.S. and South Jersey

The data on opioid use disorder in the United States is sobering and well-documented. The Centers for Disease Control and Prevention tracks drug overdose deaths nationally, and the overwhelming majority involve opioids — particularly synthetic opioids like fentanyl. The pattern in New Jersey, Pennsylvania, and the broader Mid-Atlantic mirrors the national crisis.

~75%

of all U.S. drug overdose deaths in recent years have involved opioids, with synthetic opioids like fentanyl driving the majority of that count.

Centers for Disease Control and Prevention (CDC)

According to research summarized by NIDA, an estimated several million U.S. adults meet criteria for opioid use disorder in any given year. The Substance Abuse and Mental Health Services Administration documents in TIP 63 that Medication-Assisted Treatment substantially reduces opioid overdose mortality among patients retained on buprenorphine, and that retention rates double when MAT is combined with behavioral treatment compared with counseling alone.

At the local level, Camden County and the broader South Jersey region have not been spared. The American Society of Addiction Medicine’s National Practice Guideline recognizes residential treatment combined with MAT as a standard of care for moderate-to-severe opioid use disorder, particularly when co-occurring conditions are present.

The Stakes of Untreated Opioid Use

Why Specialized Opioid Treatment Matters in Camden County Recovery

Opioid use disorder is not interchangeable with other addictions. The biology is different. The withdrawal trajectory is different. The relapse profile is different. And in 2026, the overdose risk is different in a way that did not exist with the same severity even a decade ago.

Three clinical realities make specialized opioid treatment essential. First, relapse risk is highest in the first weeks and months after acute withdrawal — the period when traditional "abstinence-only" rehab discharges patients home. Second, fentanyl contamination in the U.S. drug supply has made any return to use potentially fatal in a way that was less universally true with older heroin. Third, untreated co-occurring conditions drive relapse — depression, anxiety, PTSD, and chronic pain are common in opioid use disorder populations and rarely resolve on their own.

Effective residential treatment addresses all three. Medication-Assisted Treatment reduces relapse risk and overdose mortality. Integrated trauma-informed care addresses the underlying conditions. Discharge planning maintains MAT continuity into the months when overdose risk is highest. Without integrated treatment and continuity planning, relapse and overdose risks may remain significantly elevated.

Why 2026 Opioid Treatment Looks Different Than 2016

Opioid Addiction Treatment in the Fentanyl Era

The U.S. opioid landscape has shifted. According to the Centers for Disease Control and Prevention, synthetic opioids — primarily illicitly manufactured fentanyl — are now involved in the majority of U.S. opioid overdose deaths. For patients and families in South Jersey, Cherry Hill, Camden County, and Greater Philadelphia, this changes what effective treatment must address.

Six clinical realities of the fentanyl era our program is built around:

  • ●Counterfeit pills are now common. Pressed pills sold as Percocet, Xanax, or Adderall are frequently counterfeit and may contain fentanyl. Patients who believed they were using prescription pills may have been exposed to fentanyl without their knowledge.
  • ●Fentanyl contamination in heroin and stimulants. The illicit drug supply is no longer reliably what it claims to be. Heroin, cocaine, and methamphetamine samples have all been documented to contain fentanyl. There is no reliable way for a person using to know dose, potency, or what is actually in any unregulated substance.
  • ●Overdose unpredictability. Fentanyl is potent in microgram quantities. A small variation in concentration between batches — or within a single batch — can be the difference between a tolerated dose and a fatal one.
  • ●Naloxone (Narcan) education and access. We educate patients and families on opioid overdose recognition and naloxone administration. Patients leave residential with discharge planning that includes naloxone access information for themselves and the people in their household.
  • ●Reduced tolerance after detox. After a period of abstinence — including the days and weeks following residential treatment — opioid tolerance drops sharply. A “usual” pre-treatment dose can become a fatal dose after detox. This is one of the most documented risk windows in opioid use disorder.
  • ●Why relapse is more dangerous now than a decade ago. The combination of fentanyl-saturated supply, reduced post-treatment tolerance, and unpredictable potency means a single return-to-use event today may carry overdose risk that previous generations of relapse did not. This is why MAT continuity, naloxone education, and aftercare connection are treated as clinical priorities — not optional add-ons.

Our clinical approach to opioid use disorder is built for this reality. MAT, overdose education, naloxone access planning, and outpatient continuity are integrated into every patient’s discharge plan.

Evidence-Based, MAT-Friendly, Dual Diagnosis-Aware

How Maplewood Treats Heroin & Opioid Addiction at Our Merchantville, NJ Program

Our clinical approach to opioid use disorder, from intake through discharge:

  • ●Comprehensive medical and psychiatric intake. Patients arrive post-detox. Our medical team reviews substance use history, medication needs, mental health symptoms, and any existing MAT prescriptions on day one.
  • ●MAT continuation, confirmation, or initiation. If you arrive on Suboxone, Subutex, or Vivitrol, we continue your prescription. If your dose needs adjustment, our providers handle it. If MAT was not previously offered to you, we discuss whether it’s clinically appropriate now.
  • ●Post-acute withdrawal symptom care. Anxiety, insomnia, mood instability, and cravings often persist for weeks after acute withdrawal ends. Our psychiatric team treats these with non-habit-forming medications and ongoing clinical support.
  • ●Dual diagnosis treatment when indicated. For patients with co-occurring depression, anxiety, PTSD, bipolar disorder, or ADHD, our integrated Co-Occurring Disorders Program treats both conditions simultaneously.
  • ●Individual and group therapy. Evidence-based modalities including CBT, DBT, motivational interviewing, and relapse prevention skills work.
  • ●Trauma-informed clinical environment. Many patients with opioid use disorder have trauma histories. Our trauma-informed care framework shapes every interaction, from intake conversations to group facilitation.
  • ●Family work when clinically appropriate. Opioid addiction affects the family system. Our family therapy work, led by a Licensed Associate Marriage and Family Therapist, is integrated into residential care.
  • ●MAT continuity into aftercare. Before discharge, your case manager connects you to an outpatient prescriber who continues your MAT prescription. No gap. No interruption. Continuity of MAT and outpatient care is strongly associated with improved long-term recovery outcomes and reduced relapse risk during the high-risk post-residential transition period.

Every component is integrated. None of it operates in isolation. That integration is what makes residential treatment for opioid use disorder more than the sum of its parts.

Inside the Residential Stay

What Opioid Use Disorder Patients Receive at Our South Jersey Program

Comprehensive Medical Evaluation
Medical and psychiatric assessment at admission to inform every medication and treatment decision.
MAT Continuation & Initiation
Suboxone, Subutex, Sublocade, oral or injectable Vivitrol — continued, dosage-confirmed, or newly prescribed.
Post-Acute Withdrawal Care
Treatment for the lingering anxiety, insomnia, mood symptoms, and cravings that often follow acute opioid withdrawal.
Dual Diagnosis Assessment
Comprehensive evaluation for co-occurring depression, anxiety, PTSD, bipolar disorder, and other mental health conditions.
Individual & Group Therapy
CBT, DBT, motivational interviewing, relapse prevention, trauma-informed and family-inclusive sessions.
MAT Discharge Continuity
Case management connects you to an outpatient MAT prescriber before you leave residential. No gap, no taper, no interruption.

The Treatment Continuum — Built Into Discharge Planning

What Happens After Residential Opioid Treatment?

Residential is the beginning of treatment, not the end of it. The weeks and months after discharge are clinically the highest-risk period for relapse and overdose — particularly in the fentanyl era. Continuity of care across the levels below is associated with improved long-term recovery outcomes and reduced relapse risk. Before you leave Maplewood, your case manager builds a discharge plan that connects you to the right next step for your situation.

Partial Hospitalization (PHP)
Day-program structure most days of the week. Highest-intensity outpatient level. Appropriate when a patient needs continued clinical structure but no longer requires 24-hour residential care.
Intensive Outpatient (IOP)
Group and individual therapy several times per week. Allows patients to return to work, school, or family responsibilities while keeping clinical structure in place.
Standard Outpatient (OP)
Weekly therapy and check-ins. Often the long-term level patients step down into and remain in for months to years of recovery support.
MAT Continuation
Before you leave, we connect you to an outpatient prescriber who continues your Suboxone, Subutex, Sublocade, or Vivitrol. No gap in prescription. No starting over.
Therapy Continuity
Individual therapy referrals to clinicians in the patient’s home area, in-network, and trauma-informed where indicated. Continuity of relationship matters in early recovery.
Relapse Prevention Planning
Written, individualized relapse-prevention plan covering high-risk situations, coping skills, support contacts, and overdose response — including naloxone access information.
Outpatient Referrals
Coordinated referrals to PHP, IOP, OP, or psychiatric providers near the patient’s home in South Jersey, Greater Philadelphia, or wherever the patient is returning.
Sober Living Options
For patients who would benefit from a structured living environment after residential, our team helps identify recovery residences that align with the patient’s plan.
Alumni & Ongoing Support
Maplewood maintains a connection with patients after discharge through alumni outreach and check-ins, recovery community resources, and family support touchpoints.

The right step-down depends on the patient’s clinical picture, home environment, employment, family system, and insurance. Discharge planning at Maplewood is individualized, built into the residential stay — not handed over at the door.

When to Reach Out for Help

Signs of Opioid Use Disorder — What to Watch For

Opioid use disorder rarely appears all at once. The patterns build over weeks or months, often in ways that are easier to see from outside than inside. Below are the signs and symptoms most often present when residential treatment is the right next step. None of these alone is conclusive — but several together is a clinical signal worth acting on.

Increasing tolerance — needing more for the same effect
Withdrawal symptoms when not using
Multiple failed attempts to cut down or quit
Lost time managing obtaining, using, recovering
Pinpoint pupils, drowsiness, nodding off
Continuing use despite job, family, or health consequences
Doctor-shopping for prescription opioids
Using more or longer than intended
Mood swings, secrecy, social withdrawal
Recent overdose or close call
Concerns about fentanyl in the supply
Co-occurring depression, anxiety, or PTSD

Real Search Queries, Real Answers

Questions People Ask Before Entering Treatment for Heroin or Opioid Addiction

The questions our admissions team hears most often from patients and families weighing residential treatment for opioid use disorder:

“Will I lose my Suboxone prescription in residential rehab?”
“Heroin addiction treatment near Cherry Hill NJ — what are my options?”
“How long does residential treatment for opioid addiction take?”
“Is fentanyl addiction treated differently than heroin?”
“Residential opioid rehab near Philadelphia that accepts my insurance”
“Can I get residential treatment for prescription painkiller addiction?”
“What about MAT for opioid use disorder near me?”
“Opioid addiction treatment for someone with depression and anxiety”

Every one of these gets the same posture from our admissions team: we continue MAT, we treat co-occurring conditions, and we work with you to plan continuity into outpatient care. Verify your insurance benefits or call to discuss your specific situation.

Common Questions Patients & Families Ask

Frequently Asked Questions About Heroin & Opioid Treatment in South Jersey

What is the difference between heroin addiction and prescription opioid addiction?
Clinically, both fall under the same diagnostic category — opioid use disorder. The substances act on the same receptors and produce similar dependence patterns. The differences are practical: prescription opioid addiction often begins with legitimate medical use and may involve doctor-shopping or pharmacy patterns; heroin and illicit fentanyl use carry higher overdose risk due to inconsistent potency and contamination. Maplewood treats both within the same residential program, with treatment plans tailored to each patient’s specific history.
Will I be able to continue my Suboxone or Vivitrol at Maplewood?
Yes. Bring your medication in its original pharmacy bottle and your prescriber’s contact information. Our clinical team continues your MAT prescription throughout the residential stay. We do not force taper. We do not require "detoxing off it first." This is the most common scenario we see at admission, and continuity is the standard. For more, see our MAT page.
How long does residential treatment for opioid use disorder typically take?
Length of stay is individualized based on clinical assessment, insurance authorization, and patient progress. Many patients with opioid use disorder benefit from 30, 60, or 90 days of residential care, particularly when co-occurring conditions are involved. Your clinical team will discuss recommended length and adjust as needed throughout the stay.
How is treatment for fentanyl addiction different from heroin?
Clinically, the treatment is similar — opioid use disorder is treated as a chronic condition regardless of which specific opioid the patient was using. The most significant difference is risk profile: fentanyl is dramatically more potent than heroin, meaning overdose risk on relapse is higher and the urgency of MAT and aftercare continuity is higher. Our discharge planning is calibrated for this risk, with explicit MAT continuity to outpatient providers.
Does insurance cover residential opioid addiction treatment?
Yes, in most cases. Residential treatment for opioid use disorder, including MAT, is covered as a behavioral health benefit by most major commercial insurance plans under federal parity law. Maplewood accepts Aetna, BlueCross BlueShield, Cigna, United Healthcare, AmeriHealth, Independence Blue Cross, Humana, Magellan Health, Beacon Health Options, Optum, and ComPsych. Verify your benefits at no cost.
What happens to my MAT prescription after I leave residential treatment?
Continuity is built into the discharge plan from week one of residential. Before you leave, your MAT prescription is transferred to an outpatient prescriber — your prior provider, an outpatient program in your area, or a community prescriber the case management team helps you connect with. The goal is zero gap in medication. This continuity is especially important in the first weeks after residential, when overdose risk on relapse is at its peak.

Coordinated With the Whole Program

How Opioid Treatment Integrates With the Rest of Our South Jersey Program

Opioid use disorder treatment at Maplewood is not a separate track. It is integrated with every clinical service the program offers, because effective recovery from opioid addiction rarely happens in isolation from mental health, family-system dynamics, trauma history, or aftercare planning.

Your MAT prescription is managed by the same psychiatric team handling other medication management decisions, so there is no fragmentation. Your co-occurring mental health treatment happens alongside opioid care — not after it. Trauma-informed care shapes every clinical interaction, since trauma history is common in opioid use disorder populations.

Individual therapy modalities including CBT and DBT provide skills for managing cravings, emotional reactivity, and the high-risk thinking patterns that precede relapse. Family therapy brings the system that surrounds the patient into the recovery process. For a deeper look at integrated dual diagnosis care, see our pillar guide on what dual diagnosis is.

All Treatment Programs → Meet the Clinical Team → Residential Treatment Program →

Regional Accessibility for Opioid Treatment

Heroin & Opioid Addiction Treatment Near Cherry Hill and Philadelphia

For patients and families in Cherry Hill, Marlton, Voorhees, Camden, Pennsauken, Mount Laurel, and surrounding Camden and Burlington County communities, Maplewood Treatment Solutions offers a regionally accessible option for residential heroin and opioid addiction treatment. Our Merchantville, NJ location is minutes from most South Jersey suburbs by car, and within easy reach for patients arriving from Greater Philadelphia via the Ben Franklin Bridge and Route 38.

For families navigating opioid addiction together, geographic accessibility matters in concrete ways. A parent can drop a child off without booking a hotel. A spouse can attend family therapy sessions without taking a full day off work. An adult child can drive in from Bensalem or Mount Holly for a Saturday afternoon session. These small logistics add up to better family participation throughout the residential stay.

For patients with MAT prescriptions, regional proximity also means easier coordination with outpatient prescribers near home for post-discharge care — whether your continuing prescriber is in Cherry Hill, Center City Philadelphia, Camden, Voorhees, or another nearby community. The clinical continuity that determines long-term outcomes in opioid use disorder treatment is shaped by these geographic details.

Centrally Located in South Jersey

Heroin & Opioid Treatment Across South Jersey & Greater Philadelphia

Cherry Hill Marlton Voorhees Camden Pennsauken Mount Laurel Haddonfield Greater Philadelphia

Visit Our Treatment Center

Located in Merchantville, NJ — Minutes From Cherry Hill & Philadelphia

Maplewood Treatment Solutions is located at 214 W Maple Ave in Merchantville, NJ.

Maplewood Treatment Solutions

214 W Maple Ave, Merchantville, NJ 08109

📍 Click to View Map

214 W Maple Ave, Merchantville, NJ 08109  |  (856) 485-9814

Real Stories From Real People

What South Jersey & Greater Philadelphia Clients Say About Maplewood

★★★★★ 4.8 Based on 30 Google Reviews
★★★★★

"My experience at Maplewood was life changing. The staff treated me like family and gave me the structure I needed to actually start recovery."

M
Maura F.
Google Review
★★★★★

"Maplewood gave me a real shot at recovery when I had been turned away from other places. The clinical team actually listens."

G
G.
Google Review
★★★★★

"As a family member of someone who came through Maplewood, I cannot say enough about how compassionate and professional the team is."

N
Norbert L.
Google Review
★★★★★

"Maplewood saw me as a person, not a number. Their work around dual diagnosis was exactly what I needed."

M
Meredith M.
Google Review

Evidence-Based Care, Backed by National Standards

Clinical Standards & Editorial Review at Our Merchantville, NJ Treatment Center

Content on this page is informed by evidence-based opioid use disorder treatment principles and reviewed against recognized clinical standards from the following authoritative bodies:

SAMHSA TIP 63 — Medications for Opioid Use Disorder
Federal Treatment Improvement Protocol on buprenorphine, methadone, and naltrexone.
NIDA — Opioids Research
National Institute on Drug Abuse research on opioid use disorder, medications, and treatment outcomes.
CDC — Drug Overdose Surveillance
Centers for Disease Control data on drug overdose deaths, fentanyl exposure, and trends.
ASAM — National Practice Guideline for OUD
American Society of Addiction Medicine guideline on standards of care for opioid use disorder.
FDA — Approved MAT Medications
Federal Drug Administration approval data and prescribing information for buprenorphine and naltrexone.
American Psychiatric Association (APA)
DSM-5 diagnostic criteria and practice guidelines for opioid use disorder.

Clinical Review & Editorial Standards

This content was clinically reviewed for accuracy regarding:

  • heroin and opioid use disorder
  • evidence-based residential addiction treatment
  • Medication-Assisted Treatment (MAT) for opioid use disorder
  • co-occurring mental health and substance use disorders
  • post-acute withdrawal symptom care

Medically & Clinically Reviewed By:

E
Medical Director, Maplewood Treatment Solutions
License: Doctor of Medicine (MD)
M
Clinical Director, Maplewood Treatment Solutions
Licenses: Licensed Clinical Alcohol & Drug Counselor (LCADC) · Licensed Associate Marriage & Family Therapist (LAMFT) · Certified Clinical Supervisor (CCS)

Last clinically reviewed: May 13, 2026

Next scheduled review: November 2026 · Review cycle: every 6 months

Maplewood Treatment Solutions content is informed by evidence-based resources including SAMHSA, NIDA, ASAM, CDC, FDA, and APA guidance where appropriate. Learn more about our clinical team and credentials: Meet the Staff →

This page is for informational purposes only and does not constitute medical advice. Opioid use disorder treatment decisions are individualized based on clinical evaluation. Maplewood Treatment Solutions is Joint Commission accredited and LegitScript certified.

Begin Admissions

Residential Opioid Treatment Near Philadelphia

If you are searching for:

  • “heroin addiction treatment near me”
  • “opioid use disorder rehab South Jersey”
  • “MAT for heroin addiction near Cherry Hill”
  • “residential opioid treatment near Philadelphia”

our team is available to help you understand your options.

No pressure. No obligation. Just information and support.